Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Turmeric's active compound curcumin suppresses melanin synthesis according to studies
Comparisons between groups were evaluated by ANOVA with a Bonferroni post-test
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
Actyl-L-Carnitine A concentrated and highly bioavailable formula for total effectiveness A concentrated and highly bioavailable formula for total effectiveness 500 mg highly bioavailable acetyl-L-carnitine (per capsule)
L-carnitine is the essential key that unlocks this barrier
